Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.51 |
| ▸ | CPA3 | P15088 | 3/20 | 0.50 |
| ▸ | LAP3 | P28838 | 3/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 2/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | CPB1 | P15086 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16898110 | 1.00 | CYP1A2 (0.55) | CYP1A2GRIK1CPA3LAP3ERAP2 | |
| SCHEMBL27675637 | 1.00 | CYP1A2 (0.55) | CYP1A2GRIK1CPA3LAP3ERAP2 | |
| SCHEMBL1857365 | 0.90 | CYP1A2 (0.61) | CYP1A2GRIK1CPA3LAP3ERAP2 | |
| SCHEMBL18241165 | 0.89 | GRIK1 (0.66) | CYP1A2GRIK1CPA3CPA1FOLH1 | |
| SCHEMBL18241164 | 0.89 | GRIK1 (0.66) | CYP1A2GRIK1CPA3CPA1FOLH1 | |
| SCHEMBL7439191 | 0.88 | GRIK1 (0.64) | CYP1A2GRIK1CPA3LAP3ERAP2 | |
| SCHEMBL7439193 | 0.88 | GRIK1 (0.64) | CYP1A2GRIK1CPA3LAP3ERAP2 | |
| Water SCHEMBL4010621 | 0.88 | CYP1A2 (0.59) | CYP1A2GRIK1CPA3LAP3ERAP2 | |
| SCHEMBL7439419 | 0.88 | GRIK1 (0.64) | CYP1A2GRIK1CPA3LAP3ERAP2 | |
| SCHEMBL3272788 | 0.86 | CYP1A2 (0.53) | CYP1A2GRIK1CPA3LAP3ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100546975-C | Midbody compound, the Its Preparation Method And Use of preparation ecadotril | SHANGHAI INST PHARM INDUSTRY (CN) | 2009-10-07 | — | — | CN | claimed |
| CN-100537531-C | Preparation process of cadotril | SHANGHAI INST OF MEDICINE INDU (CN) | 2009-09-09 | — | — | CN | claimed |
| CN-100537522-C | Intermediate compound for preparing dextro cadotril and its preparation process and use | SHANGHAI INST OF MEDICINE INDU (CN) | 2009-09-09 | — | — | CN | claimed |
| CN-1931829-A | Intermediate compound for preparing ecadotril and its prepn process and use | SHANGHAI INST OF MEDICINE INDU (CN) | 2007-03-21 | — | — | CN | claimed |
| CN-1931830-A | Intermediate compound for preparing dextro cadotril and its prepn process and use | SHANGHAI INST OF MEDICINE INDU (CN) | 2007-03-21 | — | — | CN | claimed |
| CN-1931837-A | Prepn process of cadotril | SHANGHAI INST OF MEDICINE INDU (CN) | 2007-03-21 | — | — | CN | claimed |
| US-20200095217-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-03-26 | — | — | US | disclosed |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| CN-109970797-A | Hydroxyformamide derivatives and application thereof | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-106103431-B | Hydroxycarboxamide derivatives and their use | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2019-03-15 | — | — | CN | disclosed |
| WO-2017006295-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-12 | — | — | WO | disclosed |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| WO-2015104684-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-07-16 | — | — | WO | disclosed |
| CN-100546975-C | Midbody compound, the Its Preparation Method And Use of preparation ecadotril | SHANGHAI INST PHARM INDUSTRY (CN) | 2009-10-07 | — | — | CN | disclosed |
| CN-100537522-C | Intermediate compound for preparing dextro cadotril and its preparation process and use | SHANGHAI INST OF MEDICINE INDU (CN) | 2009-09-09 | — | — | CN | disclosed |
| CN-100537531-C | Preparation process of cadotril | SHANGHAI INST OF MEDICINE INDU (CN) | 2009-09-09 | — | — | CN | disclosed |
| CN-1931829-A | Intermediate compound for preparing ecadotril and its prepn process and use | SHANGHAI INST OF MEDICINE INDU (CN) | 2007-03-21 | — | — | CN | disclosed |
| CN-1931830-A | Intermediate compound for preparing dextro cadotril and its prepn process and use | SHANGHAI INST OF MEDICINE INDU (CN) | 2007-03-21 | — | — | CN | disclosed |
| CN-1931837-A | Prepn process of cadotril | SHANGHAI INST OF MEDICINE INDU (CN) | 2007-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095217-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | BMP1, BMPR1A, BMPR2 | CYP1A2 1422/4885GRIK1 4462/4885CPA3 3887/4885 |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | BMP1, BMPR1A, BMPR2 | CYP1A2 1422/4885GRIK1 4462/4885CPA3 3887/4885 |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | BMP1, BMPR1A, BMPR2 | CYP1A2 1422/4885GRIK1 4462/4885CPA3 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.